| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
N-Desmethyltamoxifen has multiple targets. It is a poor antiestrogen, meaning it has weak affinity for the estrogen receptor. More significantly, it is a potent inhibitor of protein kinase C (PKC), being ten-fold more potent than its parent drug, Tamoxifen. It is also an estrogen response modifier and an effective regulator of ceramide metabolism in human AML cells.
|
|---|---|
| ln Vitro |
All seven neuroastrocytoma cell lines (T98G, U87, U138, U373, ALW, AUK, and CAS cells) are significantly inhibited by N-desmethyltamoxifen hydrochloride (20–500 ng/mL; 48 hours) [1]. The human breast cancer cell line MCF 7 is inhibited in its proliferation by -desmethyltamoxifen salted (1.5-10 μM; 114 h) [2]. N-desmethyltamoxifen salted: CYP3A4/5 mediates the catalytic action of tamoxifen, which is the catalytic impact of tamoxifen.
In vitro, N-Desmethyltamoxifen is characterized as a poor antiestrogen but a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. It is an effective regulator of ceramide metabolism, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation in human AML cells. Its activity is not primarily mediated through the estrogen receptor, distinguishing it from Tamoxifen. |
| ln Vivo |
In vivo, N-Desmethyltamoxifen is the primary metabolite of Tamoxifen in humans. It contributes to the overall pharmacological profile and metabolism of the parent drug. Its role in vivo is understood through pharmacokinetic studies, where its concentration is monitored. Its potent PKC inhibitory activity may contribute to some of the therapeutic and side effects of Tamoxifen therapy.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for N-Desmethyltamoxifen involve measuring its affinity for the estrogen receptor and its inhibition of protein kinase C (PKC). Estrogen receptor binding can be assessed using radioligand binding studies with ³H-estradiol. PKC inhibition is measured using kinase activity assays with a specific peptide substrate and ³³P-ATP, where the compound's IC50 is determined and compared to Tamoxifen.
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: MCF 7 human breast cancer cells Tested Concentrations: 1.5, 2.5, 5, 7.5, 10 μM Incubation Duration: 114 hrs (hours) Experimental Results: Inhibition of the growth of MCF 7 human breast cancer cells For in vitro cell-based assays, cells expressing the estrogen receptor (e.g., MCF-7 breast cancer cells) are cultured and treated with the compound. Its poor antiestrogenic activity is confirmed by its weak ability to inhibit estrogen-stimulated cell proliferation. Its effects on PKC signaling can be assessed by measuring the phosphorylation of PKC substrates. Its role in ceramide metabolism can be studied in AML cell lines. |
| Animal Protocol |
In vivo animal studies with N-Desmethyltamoxifen are primarily pharmacokinetic, as it is a major metabolite. The compound is administered to rodents, and blood and tissue samples are collected to study its formation, distribution, and elimination. Its effects, if any, would be studied in the context of Tamoxifen administration, where it is formed as a major metabolite.
|
| ADME/Pharmacokinetics |
N-Desmethyltamoxifen HCl (CAS: 15917-65-4) has a molecular weight of 393.95 g/mol and a molecular formula of C25H28ClNO. It is the hydrochloride salt of the primary metabolite of Tamoxifen. It is a solid and is typically stored at room temperature. It is an essential research compound for oncology, endocrinology, and drug metabolism investigations. It is also used as an internal standard in HPLC.
|
| Toxicity/Toxicokinetics |
N-Desmethyltamoxifen is a research compound and is not approved for therapeutic use. Its toxicity is primarily studied in the context of Tamoxifen metabolism. As a metabolite, it is expected to have a similar but not identical profile. Tamoxifen has known side effects, including an increased risk of endometrial cancer and thromboembolic events. The compound is not intended for human therapeutic use.
|
| References |
|
| Additional Infomation |
N-Desmethyltamoxifen HCl is the primary metabolite of Tamoxifen in humans. It is a poor antiestrogen but a ten-fold more potent protein kinase C (PKC) inhibitor. It is also a regulator of ceramide metabolism. It is a valuable research tool for studying Tamoxifen metabolism and the pharmacology of its metabolites. It is not an approved drug.
|
| Molecular Formula |
C25H27NO.HCL
|
|---|---|
| Molecular Weight |
393.94892
|
| Exact Mass |
393.186
|
| CAS # |
15917-65-4
|
| Related CAS # |
N-Desmethyltamoxifen;31750-48-8
|
| PubChem CID |
24200424
|
| Appearance |
White to off-white solid powder
|
| Density |
1.047g/cm3
|
| Boiling Point |
485.8ºC at 760mmHg
|
| Melting Point |
225-227ºC
|
| Flash Point |
213.2ºC
|
| Vapour Pressure |
8.21E-11mmHg at 25°C
|
| LogP |
6.846
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
28
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3.Cl
|
| InChi Key |
GMLHJWZEYLTNJW-BJFQDICYSA-N
|
| InChi Code |
InChI=1S/C25H27NO.ClH/c1-3-24(20-10-6-4-7-11-20)25(21-12-8-5-9-13-21)22-14-16-23(17-15-22)27-19-18-26-2;/h4-17,26H,3,18-19H2,1-2H3;1H/b25-24-;
|
| Chemical Name |
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N-methylethanamine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~158.65 mM)
H2O : ~1 mg/mL (~2.54 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5384 mL | 12.6920 mL | 25.3839 mL | |
| 5 mM | 0.5077 mL | 2.5384 mL | 5.0768 mL | |
| 10 mM | 0.2538 mL | 1.2692 mL | 2.5384 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
